258 related articles for article (PubMed ID: 26338962)
1. A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme.
Galore-Haskel G; Nemlich Y; Greenberg E; Ashkenazi S; Hakim M; Itzhaki O; Shoshani N; Shapira-Fromer R; Ben-Ami E; Ofek E; Anafi L; Besser MJ; Schachter J; Markel G
Oncotarget; 2015 Oct; 6(30):28999-9015. PubMed ID: 26338962
[TBL] [Abstract][Full Text] [Related]
2. ADAR1-mediated regulation of melanoma invasion.
Nemlich Y; Baruch EN; Besser MJ; Shoshan E; Bar-Eli M; Anafi L; Barshack I; Schachter J; Ortenberg R; Markel G
Nat Commun; 2018 May; 9(1):2154. PubMed ID: 29855470
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth.
Nemlich Y; Greenberg E; Ortenberg R; Besser MJ; Barshack I; Jacob-Hirsch J; Jacoby E; Eyal E; Rivkin L; Prieto VG; Chakravarti N; Duncan LM; Kallenberg DM; Galun E; Bennett DC; Amariglio N; Bar-Eli M; Schachter J; Rechavi G; Markel G
J Clin Invest; 2013 Jun; 123(6):2703-18. PubMed ID: 23728176
[TBL] [Abstract][Full Text] [Related]
4. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis.
Shoshan E; Mobley AK; Braeuer RR; Kamiya T; Huang L; Vasquez ME; Salameh A; Lee HJ; Kim SJ; Ivan C; Velazquez-Torres G; Nip KM; Zhu K; Brooks D; Jones SJ; Birol I; Mosqueda M; Wen YY; Eterovic AK; Sood AK; Hwu P; Gershenwald JE; Robertson AG; Calin GA; Markel G; Fidler IJ; Bar-Eli M
Nat Cell Biol; 2015 Mar; 17(3):311-21. PubMed ID: 25686251
[TBL] [Abstract][Full Text] [Related]
5. ADAR1p150 regulates the biosynthesis and function of miRNA-149* in human melanoma.
Yujie Ding MM; Shi X; Ji J; Su Y
Biochem Biophys Res Commun; 2020 Mar; 523(4):900-907. PubMed ID: 31959472
[TBL] [Abstract][Full Text] [Related]
6. RNA editing enzyme ADAR1 controls miR-381-3p-mediated expression of multidrug resistance protein MRP4 via regulation of circRNA in human renal cells.
Omata Y; Okawa M; Haraguchi M; Tsuruta A; Matsunaga N; Koyanagi S; Ohdo S
J Biol Chem; 2022 Aug; 298(8):102184. PubMed ID: 35753353
[TBL] [Abstract][Full Text] [Related]
7. ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis.
Karki R; Sundaram B; Sharma BR; Lee S; Malireddi RKS; Nguyen LN; Christgen S; Zheng M; Wang Y; Samir P; Neale G; Vogel P; Kanneganti TD
Cell Rep; 2021 Oct; 37(3):109858. PubMed ID: 34686350
[TBL] [Abstract][Full Text] [Related]
8. Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells.
Margolis N; Moalem H; Meirson T; Galore-Haskel G; Markovits E; Baruch EN; Vizel B; Yeffet A; Kanterman-Rifman J; Debby A; Besser MJ; Schachter J; Markel G
Cancer Immunol Res; 2022 Sep; 10(9):1127-1140. PubMed ID: 35731225
[TBL] [Abstract][Full Text] [Related]
9. Combinatory RNA-Sequencing Analyses Reveal a Dual Mode of Gene Regulation by ADAR1 in Gastric Cancer.
Cho CJ; Jung J; Jiang L; Lee EJ; Kim DS; Kim BS; Kim HS; Jung HY; Song HJ; Hwang SW; Park Y; Jung MK; Pack CG; Myung SJ; Chang S
Dig Dis Sci; 2018 Jul; 63(7):1835-1850. PubMed ID: 29691780
[TBL] [Abstract][Full Text] [Related]
10. ADAR1 Suppresses Interferon Signaling in Gastric Cancer Cells by MicroRNA-302a-Mediated IRF9/STAT1 Regulation.
Jiang L; Park MJ; Cho CJ; Lee K; Jung MK; Pack CG; Myung SJ; Chang S
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867271
[TBL] [Abstract][Full Text] [Related]
11. A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.
Nakano M; Fukami T; Gotoh S; Nakajima M
J Biol Chem; 2017 Mar; 292(12):4873-4884. PubMed ID: 28188287
[TBL] [Abstract][Full Text] [Related]
12. Circular RNA hsa_circ_0004872 inhibits gastric cancer progression via the miR-224/Smad4/ADAR1 successive regulatory circuit.
Ma C; Wang X; Yang F; Zang Y; Liu J; Wang X; Xu X; Li W; Jia J; Liu Z
Mol Cancer; 2020 Nov; 19(1):157. PubMed ID: 33172486
[TBL] [Abstract][Full Text] [Related]
13. Immune-related IncRNA LINC00944 responds to variations in ADAR1 levels and it is associated with breast cancer prognosis.
de Santiago PR; Blanco A; Morales F; Marcelain K; Harismendy O; Sjöberg Herrera M; Armisén R
Life Sci; 2021 Mar; 268():118956. PubMed ID: 33383047
[TBL] [Abstract][Full Text] [Related]
14. Adenosine deaminase acting on RNA-1 (ADAR1) inhibits hepatitis B virus (HBV) replication by enhancing microRNA-122 processing.
Liu G; Ma X; Wang Z; Wakae K; Yuan Y; He Z; Yoshiyama H; Iizasa H; Zhang H; Matsuda M; Sugiyama R; Yuan Z; Muramatsu M; Li L
J Biol Chem; 2019 Sep; 294(38):14043-14054. PubMed ID: 31366735
[TBL] [Abstract][Full Text] [Related]
15. ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity.
Ramírez-Moya J; Baker AR; Slack FJ; Santisteban P
Oncogene; 2020 Apr; 39(18):3738-3753. PubMed ID: 32157211
[TBL] [Abstract][Full Text] [Related]
16. Calreticulin regulates the expression of MMP14 and ADAR1 through EIF2AK2 signaling to promote the proliferation and progression of malignant melanoma cells.
Liang L; Wang J; Guo T; Huang L; Wu Y; Xu R; Huang T; Ma B
Neoplasma; 2024 Apr; 71(2):180-192. PubMed ID: 38766853
[TBL] [Abstract][Full Text] [Related]
17. ADAR1 regulates ARHGAP26 gene expression through RNA editing by disrupting miR-30b-3p and miR-573 binding.
Wang Q; Hui H; Guo Z; Zhang W; Hu Y; He T; Tai Y; Peng P; Wang L
RNA; 2013 Nov; 19(11):1525-36. PubMed ID: 24067935
[TBL] [Abstract][Full Text] [Related]
18. ADAR1 promotes the epithelial-to-mesenchymal transition and stem-like cell phenotype of oral cancer by facilitating oncogenic microRNA maturation.
Liu X; Fu Y; Huang J; Wu M; Zhang Z; Xu R; Zhang P; Zhao S; Liu L; Jiang H
J Exp Clin Cancer Res; 2019 Jul; 38(1):315. PubMed ID: 31315644
[TBL] [Abstract][Full Text] [Related]
19. ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis.
Zipeto MA; Court AC; Sadarangani A; Delos Santos NP; Balaian L; Chun HJ; Pineda G; Morris SR; Mason CN; Geron I; Barrett C; Goff DJ; Wall R; Pellecchia M; Minden M; Frazer KA; Marra MA; Crews LA; Jiang Q; Jamieson CHM
Cell Stem Cell; 2016 Aug; 19(2):177-191. PubMed ID: 27292188
[TBL] [Abstract][Full Text] [Related]
20. An immune-active tumor microenvironment favors clinical response to ipilimumab.
Ji RR; Chasalow SD; Wang L; Hamid O; Schmidt H; Cogswell J; Alaparthy S; Berman D; Jure-Kunkel M; Siemers NO; Jackson JR; Shahabi V
Cancer Immunol Immunother; 2012 Jul; 61(7):1019-31. PubMed ID: 22146893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
